Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?

Kyu Yeon Hur

doi:10.4093/dmj.2014.38.6.437

Articles

Page Path: HOME > Diabetes Metab J > Volume 38(6); 2014 > Article

Editorial Others Is GDF15 a Novel Biomarker to Predict the Development of Prediabetes or Diabetes?: Kyu Yeon Hur; Diabetes & Metabolism Journal 2014;38(6):437-438.
DOI: https://doi.org/10.4093/dmj.2014.38.6.437
Published online: December 15, 2014

2,631 Views
28 Download
7 Web of Science
7 Crossref
7 Scopus

Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Corresponding author: Kyu Yeon Hur. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. ky.hur@samsung.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

NOTES
REFERENCES

Growth differentiation factor 15 (GDF15) was discovered as a divergent member of the transforming growth factor β (TGF-β) superfamily. GDF15 was cloned independently in different laboratories and is therefore also known as different names including macrophage inhibitory cytokine-1 [1], nonsteroidal anti-inflammatory drug-activated gene-1 [2], placental bone morphogenetic protein B [3], and placental transforming growth factor β [4]. It is expressed in various cells including macrophages, cardiomyocytes, adipocytes, smooth muscle cells, and endothelial cells.

In terms of inflammation, GDF15 has anti-inflammatory characteristics. Proinflammatory cytokines like interleukin 1β (IL-1β) and TNF-α stimulates GDF15 [1], which in turn stimulates adiponectin. Adiponectin is a well-known anti-inflammatory protein whose circulating levels are decreased before type 2 diabetes [5]. This finding suggests that GDF15 may also play a role in compensatory anti-inflammatory response in type 2 diabetes.

GDF15 showed some conflicting results in obesity and weight loss. Circulating levels of GDF15 showed a positive correlation with obesity or body mass index (BMI) in several previous studies [6,7]. However, Framingham Offspring study reported that GDF15 had no association with BMI [8], and other studies even demonstrated that increased levels of GDF15 was in parallel with weight loss after bariatric surgery [9].

In glucose metabolism, GDF15 had similar characteristics to IL-1 receptor antagonist and TGF-β1 rather than adiponectin. Previous representative studies, such as Whitehall II cohort study [6] and the XENical in the prevention of Diabetes in Obese Subjects study [7] showed that higher circulating levels of GDF15 were associated with higher risk of type 2 diabetes.

Hong et al. [10] showed that GDF15 had a positive correlation with insulin resistance independent of age and BMI, and the serum level of GDF15 had a positive correlation with impaired fasting glucose and type 2 diabetes and insisted that GDF15 may be a novel biomarker for detecting impaired fasting glucose. However, this is a cross-sectional study, not a prospective study. So the efficacy of GDF15 as a biomarker to detect prediabetes instead of oral glucose tolerance test or hemoglobin A1c should be confirmed in a prospective study using oral glucose tolerance test.

NOTES

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;94:11514-11519. PubMed PMC
2. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-908. Article PubMed
3. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997;1354:40-44. Article PubMed
4. Lawton LN, Bonaldo MF, Jelenc PC, Qiu L, Baumes SA, Marcelino RA, de Jesus GM, Wellington S, Knowles JA, Warburton D, Brown S, Soares MB. Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 1997;203:17-26. Article PubMed
5. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009;150:1688-1696. Article PubMed
6. Carstensen M, Herder C, Brunner EJ, Strassburger K, Tabak AG, Roden M, Witte DR. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol 2010;162:913-917. Article PubMed
7. Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M, Wollert KC. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol 2012;167:671-678. Article PubMed
8. Ho JE, Mahajan A, Chen MH, Larson MG, McCabe EL, Ghorbani A, Cheng S, Johnson AD, Lindgren CM, Kempf T, Lind L, Ingelsson E, Vasan RS, Januzzi J, Wollert KC, Morris AP, Wang TJ. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 2012;58:1582-1591. Article PubMed PMC PDF
9. Vila G, Riedl M, Anderwald C, Resl M, Handisurya A, Clodi M, Prager G, Ludvik B, Krebs M, Luger A. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011;57:309-316. Article PubMed PDF
10. Hong JH, Chung HK, Park HY, Joung KH, Lee JH, Jung JG, Kim KS, Kim HJ, Ku BJ, Shong M. GDF15 is a novel biomarker for impaired fasting glucose. Diabetes Metab J 2014;38:472-479.Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

Identification of potential lncRNAs and co-expressed mRNAs in gestational diabetes mellitus by RNA sequencing
Tao Li, Die Hu, Yunhui Gong
The Journal of Maternal-Fetal & Neonatal Medicine.2024; 35(25): 5125. CrossRef
Towards frailty biomarkers: Candidates from genes and pathways regulated in aging and age-related diseases
Ana Luisa Cardoso, Adelaide Fernandes, Juan Antonio Aguilar-Pimentel, Martin Hrabě de Angelis, Joana Ribeiro Guedes, Maria Alexandra Brito, Saida Ortolano, Giovambattista Pani, Sophia Athanasopoulou, Efstathios S. Gonos, Markus Schosserer, Johannes Grilla
Ageing Research Reviews.2018; 47: 214. CrossRef
Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis
Yingyu Song, Yang Cui, Xiao Zhang, Haobo Lin, Guangfeng Zhang, Hui Zeng, Yonghan Zeng
Medicine.2018; 97(51): e13733. CrossRef
Mechanisms regulating intestinal barrier integrity and its pathological implications
Chaithanya Chelakkot, Jaewang Ghim, Sung Ho Ryu
Experimental & Molecular Medicine.2018; 50(8): 1. CrossRef
Multi–omic analysis of signalling factors in inflammatory comorbidities
Hui Xiao, Krzysztof Bartoszek, Pietro Lio’
BMC Bioinformatics.2018;[Epub] CrossRef
Letter: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
Bo Kyung Koo
Diabetes & Metabolism Journal.2015; 39(1): 82. CrossRef
Response: GDF15 Is a Novel Biomarker for Impaired Fasting Glucose (Diabetes Metab J2014;38:472-9)
Jun Hwa Hong, Bon Jeong Ku, Minho Shong
Diabetes & Metabolism Journal.2015; 39(1): 84. CrossRef

PubReader

Cite

CITE: export Copy Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.